IGHE and cancer: The product, MOv18 IgE (an IgE directed towards the tumour-associated antigen, folate receptor-alpha), was manufactured at the Cancer Research UK, Biotherapeutics Unit for a phase I clinical trial (CRUKD/14/001; EudraCT number 2014-000070-19) in patients with advanced malignancies, in the United Kingdom (UK).